There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
In Switzerland, intravenous drug use accounts for the majority of hepatitis C virus
(HCV) infections. Early HCV treatment prevents further transmissions and reduces morbidity
and mortality due to decompensated liver cirrhosis and hepatocellular carcinoma. Nevertheless,
patients in drug substitution programmes are often insufficiently screened and treated.